Bruker (BRKR) Expected to Announce Earnings on Wednesday

by · The Cerbat Gem

Bruker (NASDAQ:BRKR – Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $763.83 million for the quarter. Bruker has set its FY 2025 guidance at 2.670-2.720 EPS.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Stock Performance

NASDAQ BRKR opened at $40.73 on Tuesday. The company’s 50 day moving average is $41.85 and its 200-day moving average is $51.68. The firm has a market cap of $6.17 billion, a P/E ratio of 53.59, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. Bruker has a 12-month low of $34.10 and a 12-month high of $79.78. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. Bruker’s payout ratio is 26.32%.

Analyst Ratings Changes

BRKR has been the subject of several recent research reports. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Citigroup decreased their price target on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, April 7th. Barclays reduced their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Stifel Nicolaus lowered their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $65.00.

Check Out Our Latest Research Report on BRKR

Bruker Company Profile

(Get Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Featured Articles